{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:16:05Z","timestamp":1790907365924,"version":"4.1.0"},"reference-count":291,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T00:00:00Z","timestamp":1703980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.blre.2023.101141","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T23:38:18Z","timestamp":1699659498000},"page":"101141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["The many facets of immune-mediated thrombocytopenia: Principles of immunobiology and immunotherapy"],"prefix":"10.1016","volume":"63","author":[{"given":"Thomas","family":"Moulinet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Moussu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2023.101141_bb0005","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"Moulis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood.2020004888","article-title":"Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2023.101141_bb0020","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","article-title":"The ITP syndrome: pathogenic and clinical diversity","volume":"113","author":"Cines","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0025","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune thrombocytopenia: recent advances in pathogenesis and treatments","volume":"5","author":"Audia","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.blre.2023.101141_bb0030","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3324\/haematol.2021.279442","article-title":"Immune thrombocytopenia following vaccination during the COVID-19 pandemic","volume":"107","author":"Choi","year":"2021","journal-title":"Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.18686","article-title":"Increased incidence of immune thrombocytopenia (ITP) in 2021 correlating with the ongoing vaccination campaign against COVID -19 in a tertiary center \u2013 a monocentric analysis","volume":"201","author":"Schaefers","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0040","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood.2021013411","article-title":"SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP","volume":"139","author":"Lee","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0045","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1007\/s42399-020-00521-8","article-title":"Immune thrombocytopenia secondary to COVID-19: a systematic review","volume":"2","author":"Bhattacharjee","year":"2020","journal-title":"SN Compr Clin Med"},{"key":"10.1016\/j.blre.2023.101141_bb0050","article-title":"Immune thrombocytopenic Purpura (ITP) following natural COVID-19 infection","volume":"14","author":"Santhosh","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.blre.2023.101141_bb0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40164-023-00403-4","article-title":"New approaches to idiopathic neutropenia in the era of clonal hematopoiesis","volume":"12","author":"Ogbue","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101141_bb0060","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminhematol.2008.12.005","article-title":"Pathobiology of secondary immune thrombocytopenia","volume":"46","author":"Cines","year":"2009","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb0065","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/asheducation-2018.1.576","article-title":"Drug-associated thrombocytopenia","volume":"2018","author":"Bakchoul","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2023.101141_bb0070","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood.V87.10.4245.bloodjournal87104245","article-title":"Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity","volume":"87","author":"Semple","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0075","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00277-008-0535-3","article-title":"Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura","volume":"87","author":"Ma","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb0080","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4049\/jimmunol.1200580","article-title":"Platelets present antigen in the context of MHC class I","volume":"189","author":"Chapman","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0085","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1182\/bloodadvances.2017007021","article-title":"Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets","volume":"1","author":"Zufferey","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101141_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia","volume":"76","author":"Provan","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.blre.2023.101141_bb0095","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022018380","article-title":"The role of CD8+ T cell clones in immune thrombocytopenia","author":"Malik","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0100","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16334","article-title":"Increased cytotoxic potential of CD8 + T cells in immune thrombocytopenia","volume":"188","author":"Vrbensky","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0105","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1160\/TH12-01-0012","article-title":"Increased plasma levels of granzymes in adult patients with chronic immune thrombocytopenia","volume":"107","author":"Olsson","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2023.101141_bb0110","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0115","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2008-02-139402","article-title":"Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1","volume":"112","author":"Olsson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0120","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2141.2007.06737.x","article-title":"CD8 + T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura","volume":"139","author":"Li","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0125","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1182\/blood-2009-09-244772","article-title":"A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy","volume":"115","author":"Chow","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0130","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2015-06-655126","article-title":"CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia","volume":"127","author":"Guo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1600-0609.2005.00622.x","article-title":"Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura","volume":"76","author":"Zhang","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0140","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1651-2227.2004.tb02988.x","article-title":"T cell receptor V gene usage by CD4+ and CD8+ peripheral blood T lymphocytes in immune thrombocytopenic purpura","volume":"93","author":"Hedlund-Treutiger","year":"2004","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.blre.2023.101141_bb0145","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.3390\/jcm11195665","article-title":"TCR CDR3 sequencing as a clue to elucidate the landscape of Dysimmunity in patients with primary immune thrombocytopenia","volume":"11","author":"Ji","year":"2022","journal-title":"JCM"},{"key":"10.1016\/j.blre.2023.101141_bb0150","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell\u2013depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0155","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41379-020-0568-2","article-title":"T-cell clones of uncertain significance are highly prevalent and show close resemblance to T-cell large granular lymphocytic leukemia. Implications for laboratory diagnostics","volume":"33","author":"Shi","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2023.101141_bb0160","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.exphem.2006.03.009","article-title":"Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes","volume":"34","author":"Catani","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb0165","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1600-0609.2011.01745.x","article-title":"Circulating plasmacytoid dendritic cells in patients with primary and Helicobacter pylori-associated immune thrombocytopenia: Plasmacytoid dendritic cells in ITP","volume":"88","author":"Saito","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0170","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00277-012-1556-5","article-title":"Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia","volume":"92","author":"Catani","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb0175","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.2830370409","article-title":"Suppressed natural killer cell activity in patients with chronic autoimmune thrombocytopenic purpura","volume":"37","author":"Semple","year":"1991","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb0180","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/bjh.18818","article-title":"Assessment of circulating blood lymphocytes in adult patients on rituximab to treat immune thrombocytopenia: circulating number of NK cells is associated with the response at 6months","volume":"202","author":"Rivi\u00e8re","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0185","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clim.2015.11.005","article-title":"NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia","volume":"177","author":"Ebbo","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0190","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1016\/j.celrep.2018.08.075","article-title":"Affinity maturation is impaired by natural killer cell suppression of germinal centers","volume":"24","author":"Rydyznski","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2023.101141_bb0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1189\/jlb.4HI1214-594R","article-title":"NK cells inhibit humoral immunity by reducing the abundance of CD4+ T follicular helper cells during a chronic virus infection","volume":"98","author":"Cook","year":"2015","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.blre.2023.101141_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2020.102529","article-title":"Myeloid-derived suppressor cells anticipate sustained treatment response in newly-diagnosed and persistent primary immune thrombocytopenia","volume":"87","author":"Elsaied","year":"2021","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2023.101141_bb0205","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood-2015-10-674531","article-title":"High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia","volume":"127","author":"Hou","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0210","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.14542","article-title":"Intravenous immunoglobulin treatment of spleen cells from patients with immune thrombocytopenia significantly increases the percentage of myeloid-derived suppressor cells","volume":"181","author":"Aslam","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0215","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/0030-4220(52)90329-0","article-title":"Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura","volume":"5","author":"Bloom","year":"1952","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.blre.2023.101141_bb0220","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1182\/blood.V70.4.1040.1040","article-title":"Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP","volume":"70","author":"McMillan","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0225","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjh.15404","article-title":"Detection of platelet autoantibodies to identify immune thrombocytopenia: state of the art","volume":"182","author":"Porcelijn","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0230","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s002770050173","article-title":"Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb\/IIIa and Ib\/IX in patients with thrombocytopenia","volume":"72","author":"Kiefel","year":"1996","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb0235","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1046\/j.1365-2141.2003.04509.x","article-title":"The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb\/IIIa in patients with idiopathic thrombocytopenic purpura","volume":"122","author":"Chan","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0240","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","article-title":"Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents","volume":"116","author":"Bao","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0245","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.13648","article-title":"Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor","volume":"173","author":"Peerschke","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0250","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0609.2011.01718.x","article-title":"Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP): complement activation in ITP","volume":"88","author":"Najaoui","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0255","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2141.1985.tb07477.x","article-title":"Platelet-associated complement in chronic ITP","volume":"60","author":"Kurata","year":"1985","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0260","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune thrombocytopenia: recent advances in pathogenesis and treatments","volume":"5","author":"Audia","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.blre.2023.101141_bb0265","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/rth2.12388","article-title":"Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features","volume":"4","author":"Cheloff","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2023.101141_bb0270","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2141.2009.07995.x","article-title":"Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura","volume":"148","author":"Peerschke","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0275","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/stem.5530040606","article-title":"Complement-dependent cytotoxic factor to megakaryocyte progenitors in sera from patients with idiopathic thrombocytopenic purpura","volume":"4","author":"Usuki","year":"1986","journal-title":"Int J Cell Cloning"},{"key":"10.1016\/j.blre.2023.101141_bb0280","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/bloodadvances.2021006864","article-title":"Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia","volume":"7","author":"Broome","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101141_bb0285","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2023.101141_bb0290","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ajh.20951","article-title":"The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab","volume":"82","author":"Kuwana","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb0295","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1538-7836.2008.03161.x","article-title":"Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura","volume":"7","author":"Kuwana","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2023.101141_bb0300","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cei.12935","article-title":"Fc\u03b3 receptor expression on splenic macrophages in adult immune thrombocytopenia","volume":"188","author":"Audia","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nm.3770","article-title":"The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling","volume":"21","author":"Grozovsky","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101141_bb0310","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0076-6879(10)79013-3","article-title":"The Ashwell-Morell receptor","volume":"479","author":"Grewal","year":"2010","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.blre.2023.101141_bb0315","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1038\/ncomms8737","article-title":"Desialylation is a mechanism of fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia","volume":"6","author":"Li","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101141_bb0320","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.3324\/haematol.2021.279751","article-title":"Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia","volume":"107","author":"Zheng","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101141_bb0325","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/10245330290028605","article-title":"Major histocompatibility complex susceptibility genes and immune thrombocytopenic Purpura in Caucasian adults","volume":"7","author":"Stanworth","year":"2002","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2023.101141_bb0330","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.humimm.2005.06.004","article-title":"MHC Class I\u2013associated peptides identified from normal platelets and from individuals with idiopathic thrombocytopenic purpura","volume":"66","author":"Hopkins","year":"2005","journal-title":"Hum Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0335","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.humimm.2009.01.011","article-title":"Predisposition to idiopathic thrombocytopenic purpura maps close to the major histocompatibility complex class I chain-related gene A","volume":"70","author":"Maia","year":"2009","journal-title":"Hum Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0340","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/08820139.2011.593218","article-title":"Investigation of the possible association between the HLA antigens and idiopathic thrombocytopenic Purpura (ITP)","volume":"41","author":"Negi","year":"2012","journal-title":"Immunol Invest"},{"key":"10.1016\/j.blre.2023.101141_bb0345","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jfma.2011.06.025","article-title":"Clinical features and major histocompatibility complex genes as potential susceptibility factors in pediatric immune thrombocytopenia","volume":"111","author":"Ho","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.blre.2023.101141_bb0350","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2141.2005.05385.x","article-title":"Interleukin 4, interleukin 6 and interleukin 10 polymorphisms in children with acute and chronic immune thrombocytopenic purpura","volume":"128","author":"Wu","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0355","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2141.2006.06431.x","article-title":"High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura","volume":"136","author":"Emmerich","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0360","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2141.2010.08318.x","article-title":"Research paper: IL1RN VNTR and IL2\u2212330 polymorphic genes are independently associated with chronic immune thrombocytopenia: IL2\u2212330G and IL1RN*2 alleles in immune thrombocytopenia","volume":"150","author":"Rocha","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0365","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3109\/09537104.2011.577255","article-title":"Investigation of TNF-alpha, TGF-beta 1, IL-10, IL-6, IFN-gamma, MBL, GPIA, and IL1A gene polymorphisms in patients with idiopathic thrombocytopenic purpura","volume":"22","author":"Pehlivan","year":"2011","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2023.101141_bb0370","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-0609.2011.01651.x","article-title":"Interleukin-17F gene polymorphism in patients with chronic immune thrombocytopenia: Interleukin-17 polymorphism in chronic immune thrombocytopenic purpura","volume":"87","author":"Saitoh","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0375","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1046\/j.1365-2141.2001.02807.x","article-title":"Polymorphisms in inflammatory cytokines and Fc\u03b3 receptors in childhood chronic immune thrombocytopenic purpura: a pilot study: polymorphisms in chronic childhood ITP","volume":"113","author":"Foster","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0380","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2141.2003.04033.x","article-title":"Fc\u03b3 receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura: Fc Receptor Polymorphisms in Childhood ITP","volume":"120","author":"Carcao","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0385","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2004.05235.x","article-title":"Platelet count, previous infection and FCGR2B genotype predict development of chronic disease in newly diagnosed idiopathic thrombocytopenia in childhood: results of a prospective study: predictive factors for development of chronic childhood ITP","volume":"127","author":"Bruin","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0390","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MPH.0b013e3182580908","article-title":"Fc\u03b3 receptor gene polymorphisms in childhood immune thrombocytopenic purpura","volume":"34","author":"Amorim","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101141_bb0395","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2007-03-079913","article-title":"Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura","volume":"111","author":"Breunis","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0400","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MBC.0b013e328359bc3b","article-title":"Fc\u03b3RIIa and Fc\u03b3RIIIa polymorphisms in childhood primary immune thrombocytopenia: implications for disease pathogenesis and outcome","volume":"24","author":"Papagianni","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.blre.2023.101141_bb0405","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2015-12-688267","article-title":"A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders","volume":"127","author":"Simeoni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0410","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nri2762","article-title":"Fc\u03b3RIIB in autoimmunity and infection: evolutionary and therapeutic implications","volume":"10","author":"Smith","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0415","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nri856","article-title":"Roles of fc receptors in autoimmunity","volume":"2","author":"Takai","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0420","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3389\/fimmu.2019.00811","article-title":"Understanding fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools","volume":"10","author":"Ben Mkaddem","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0425","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.V128.22.867.867","article-title":"Fc-gamma receptor polymorphisms are associated with susceptibility to and recovery from pediatric immune thrombocytopenia","volume":"128","author":"Heitink-Polle","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0430","doi-asserted-by":"crossref","first-page":"15869","DOI":"10.1038\/ncomms15869","article-title":"Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis","volume":"8","author":"Savola","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101141_bb0435","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1038\/s41467-020-16115-w","article-title":"Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101141_bb0440","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s41591-021-01521-4","article-title":"Distinction of lymphoid and myeloid clonal hematopoiesis","volume":"27","author":"Niroula","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101141_bb0445","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2018-99-113373","article-title":"Somatic mutations in CD8+ T cells in patients with chronic immune thrombocytopenia are associated with increased Clonality and cytotoxic phenotype of CD8+ T cells","volume":"132","author":"Rajala","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0450","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2008-02-139402","article-title":"Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1","volume":"112","author":"Olsson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0455","doi-asserted-by":"crossref","first-page":"11104","DOI":"10.1073\/pnas.91.23.11104","article-title":"The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production","volume":"91","author":"Kuter","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2023.101141_bb0460","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1365-2141.1996.d01-1702.x","article-title":"Circulating thrombopoietin level in chronic immune thrombocytopenic purpura","volume":"93","author":"Kosugi","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0465","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.3390\/cells10113235","article-title":"Platelets in ITP: victims in charge of their own fate?","volume":"10","author":"Nelson","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.blre.2023.101141_bb0470","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.4049\/jimmunol.1500259","article-title":"Nouvelle cuisine: platelets served with inflammation","volume":"194","author":"Kapur","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0475","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.tmrv.2020.09.005","article-title":"The immune nature of platelets revisited","volume":"34","author":"Maouia","year":"2020","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.blre.2023.101141_bb0480","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/voxs.12554","article-title":"Platelet immunology from the inside out","volume":"15","author":"Semple","year":"2020","journal-title":"ISBT Sci Ser"},{"key":"10.1016\/j.blre.2023.101141_bb0485","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.4049\/jimmunol.1500259","article-title":"Nouvelle cuisine: platelets served with inflammation","volume":"194","author":"Kapur","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0490","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.autrev.2018.01.012","article-title":"Systemic lupus erythematosus and systemic sclerosis: all roads lead to platelets","volume":"17","author":"Scherlinger","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2023.101141_bb0495","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/eci.12101","article-title":"Platelets and autoimmunity","volume":"43","author":"Habets","year":"2013","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.blre.2023.101141_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2020.12.008","article-title":"Reduced intracellular antioxidant capacity in platelets contributes to primary immune thrombocytopenia via ROS-NLRP3-caspase-1 pathway","volume":"199","author":"Wang","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2023.101141_bb0505","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/5584_2015_162","article-title":"The influence of primary cytomegalovirus or Epstein-Barr virus infection on the course of idiopathic thrombocytopenic Purpura","volume":"878","author":"Smalisz-Skrzypczyk","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.blre.2023.101141_bb0510","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2141.2009.07714.x","article-title":"Cytomegalovirus can make immune thrombocytopenic purpura refractory","volume":"146","author":"DiMaggio","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0515","first-page":"139","article-title":"Prevalence of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) subclinical infection in patients with acute immune thrombocytopenic Purpura (ITP)","volume":"15","author":"Abbasi","year":"2021","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"10.1016\/j.blre.2023.101141_bb0520","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1179\/1607845413Y.0000000084","article-title":"The role of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) in immune thrombocytopenia","volume":"18","author":"Wu","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2023.101141_bb0525","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2141.1996.d01-1872.x","article-title":"Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP)","volume":"95","author":"Wright","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0530","doi-asserted-by":"crossref","DOI":"10.18502\/ijhoscr.v15i3.6843","article-title":"Prevalence of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) subclinical infection in patients with acute immune thrombocytopenic Purpura (ITP)","author":"Abbasi","year":"2021","journal-title":"IJHOSCR"},{"key":"10.1016\/j.blre.2023.101141_bb0535","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/08880010290097233","article-title":"Virus-associated immune thrombocytopenic purpura in childhood","volume":"19","author":"Yenicesu","year":"2002","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101141_bb0540","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-2141.2005.05542.x","article-title":"Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura","volume":"129","author":"Rajan","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0545","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0961203313499959","article-title":"Immune thrombocytopaenic purpura: an autoimmune cross-link between infections and vaccines","volume":"23","author":"Rinaldi","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.blre.2023.101141_bb0550","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/bmt.2015.252","article-title":"Characteristics and outcomes of aplastic anemia in HIV patients: a brief report from the severe aplastic anemia working party of the European Society of Blood and Bone Marrow Transplantation","volume":"51","author":"Pagliuca","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101141_bb0555","article-title":"Helicobacter pylori and autoimmune diseases: involving multiple systems","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0560","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.3390\/jcm11164822","article-title":"Helicobacter pylori infection and chronic immune thrombocytopenia","volume":"11","author":"Takeuchi","year":"2022","journal-title":"JCM"},{"key":"10.1016\/j.blre.2023.101141_bb0565","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archinte.162.9.1033","article-title":"Autoimmune thrombocytopenic purpura and Helicobacter pylori infection","volume":"162","author":"Michel","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.blre.2023.101141_bb0570","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1365-2141.2003.04735.x","article-title":"Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. Pylori-associated chronic idiopathic thrombocytopenic purpura","volume":"124","author":"Takahashi","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0575","doi-asserted-by":"crossref","DOI":"10.1111\/j.1523-5378.2007.00477.x","article-title":"Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic Purpura","volume":"12","author":"Kodama","year":"2007","journal-title":"Helicobacter"},{"key":"10.1016\/j.blre.2023.101141_bb0580","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1477-9560-11-23","article-title":"VacA, the vacuolating cytotoxin of Helicobacter pylori, binds to multimerin 1 on human platelets","volume":"11","author":"Satoh","year":"2013","journal-title":"Thrombosis J"},{"key":"10.1016\/j.blre.2023.101141_bb0585","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MOH.0b013e3282ab9904","article-title":"Secondary immune thrombocytopenic purpura","volume":"14","author":"Liebman","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb0590","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/asheducation-2008.1.206","article-title":"Helicobacter pylori and chronic ITP","volume":"2008","author":"Stasi","year":"2008","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2023.101141_bb0595","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/00042737-199908000-00010","article-title":"Determinants of Helicobacter pylori seroprevalence among Italian blood donors","volume":"11","author":"Russo","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.blre.2023.101141_bb0600","first-page":"1177","article-title":"Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura","volume":"87","author":"Veneri","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101141_bb0605","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/ajh.21125","article-title":"Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial","volume":"83","author":"Rostami","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb0610","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00277-005-1071-z","article-title":"Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura","volume":"84","author":"Tsutsumi","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb0615","first-page":"1","article-title":"Helicobacter pylori eradication in idiopathic thrombocytopenic Purpura: a meta-analysis of randomized trials","volume":"2018","author":"Kim","year":"2018","journal-title":"Gastroenterol Res Pract"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2023.101141_bb0620","first-page":"S1","article-title":"Helicobacter pylori infection in Japan: current status and future options","volume":"6","author":"Graham","year":"1994","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.blre.2023.101141_bb0625","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/0016-5085(91)90644-Z","article-title":"Epidemiology of Helicobacter pylori in an asymptomatic population in the United States","volume":"100","author":"Graham","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2023.101141_bb0630","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood-2003-03-0900","article-title":"Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura?","volume":"103","author":"Michel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0635","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1182\/blood-2006-12-062695","article-title":"Platelet-bound lipopolysaccharide enhances Fc receptor-mediated phagocytosis of IgG-opsonized platelets","volume":"109","author":"Semple","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0640","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2014-05-579110","article-title":"C-reactive protein enhances IgG-mediated phagocyte responses and thrombocytopenia","volume":"125","author":"Kapur","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0645","article-title":"Expression and prognostic value of C-reactive protein in adult immune thrombocytopenia (ITP) patients","author":"Zhang","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.blre.2023.101141_bb0650","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1007\/s42399-020-00521-8","article-title":"Immune thrombocytopenia secondary to COVID-19: a systematic review","volume":"2","author":"Bhattacharjee","year":"2020","journal-title":"SN Compr Clin Med"},{"key":"10.1016\/j.blre.2023.101141_bb0655","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1016\/j.vaccine.2021.04.054","article-title":"Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the vaccine adverse event reporting system (VAERS)","volume":"39","author":"Welsh","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.blre.2023.101141_bb0660","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood.2021013411","article-title":"SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP","volume":"139","author":"Lee","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0665","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3390\/cancers13071532","article-title":"Autoimmune complications in hematologic neoplasms","volume":"13","author":"Barcellini","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2023.101141_bb0670","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3324\/haematol.2020.272559","article-title":"Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"106","author":"Jachiet","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101141_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2020.101806","article-title":"Cancer risk in patients with primary immune thrombocytopenia - a Swedish nationwide register study","volume":"69","author":"Ekstrand","year":"2020","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.blre.2023.101141_bb0680","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00296-002-0229-4","article-title":"Malignant lymphoma-associated autoimmune diseases - a descriptive epidemiological study","volume":"22","author":"V\u00e1r\u00f3czy","year":"2002","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.blre.2023.101141_bb0685","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3389\/fonc.2019.01435","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia: focus on molecular aspects","volume":"9","author":"Fattizzo","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2023.101141_bb0690","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5144\/1658-3876.2011.100","article-title":"Successful treatment of steroid-refractory autoimmune thrombocytopenia associated with Castleman disease with anti-CD-20 antibody (rituximab)","volume":"4","author":"Ibrahim","year":"2011","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.blre.2023.101141_bb0695","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3109\/10428190903556394","article-title":"Paraneoplastic autoimmune cytopenias in Hodgkin lymphoma","volume":"51","author":"Lechner","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2023.101141_bb0700","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1053\/j.seminhematol.2008.12.004","article-title":"Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders","volume":"46","author":"Liebman","year":"2009","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb0705","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/ejh.13239","article-title":"Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma","volume":"103","author":"Crickx","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0710","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0715","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nri.2016.94","article-title":"T follicular helper cells in space-time","volume":"16","author":"Qi","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0720","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00000421-199908000-00019","article-title":"Idiopathic thrombocytopenic purpura associated with breast cancer: a case report and review of the current literature","volume":"22","author":"Porrata","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101141_bb0725","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/annonc\/mdp305","article-title":"Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP?","volume":"20","author":"Khasraw","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2023.101141_bb0730","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/09537104.2020.1822521","article-title":"Treatment of immune thrombocytopenia (ITP) secondary to malignancy: a systematic review","volume":"33","author":"Podda","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2023.101141_bb0735","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1159\/000511067","article-title":"Secondary immune thrombocytopenia in metastatic renal cell carcinoma: a case report and discussion of the literature","volume":"13","author":"Cockrell","year":"2020","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.blre.2023.101141_bb0740","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2011.02.004","article-title":"Paraneoplastic autoimmune thrombocytopenia in solid tumors","volume":"81","author":"Krauth","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb0745","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12016-010-8248-5","article-title":"The etiology of paraneoplastic autoimmunity","volume":"42","author":"Maverakis","year":"2012","journal-title":"Clinic Rev Allerg Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0750","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.613192","article-title":"Understanding immune thrombocytopenia: looking out of the box","volume":"8","author":"Schifferli","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.blre.2023.101141_bb0755","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10875-017-0456-9","article-title":"Autoimmune Cytopenias and associated conditions in CVID: a report from the USIDNET registry","volume":"38","author":"Feuille","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0760","first-page":"605","article-title":"Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus","volume":"80","author":"Nossent","year":"1991","journal-title":"Q J Med"},{"key":"10.1016\/j.blre.2023.101141_bb0765","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.autrev.2013.02.001","article-title":"Management of immune cytopenias in patients with systemic lupus erythematosus - old and new","volume":"12","author":"Newman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2023.101141_bb0770","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/rheumatology\/kel010","article-title":"Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus","volume":"45","author":"Kuwana","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.blre.2023.101141_bb0775","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2141.2008.07228.x","article-title":"Antiphospholipid antibodies in adults with immune thrombocytopenic purpura: aPL in adults with ITP","volume":"142","author":"Pierrot-Deseilligny Despujol","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0780","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bjh.12318","article-title":"Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies","volume":"161","author":"Kim","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0785","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1182\/blood.V84.12.4203.bloodjournal84124203","article-title":"Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura","volume":"84","author":"Stasi","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0790","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0609.2007.00998.x","article-title":"Epidemiology and pathophysiology of immune thrombocytopenic purpura: epidemiology and pathophysiology of ITP","volume":"80","author":"Gernsheimer","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0795","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1046\/j.1365-2141.1997.3063123.x","article-title":"Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome","volume":"98","author":"Godeau","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0800","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.autrev.2015.11.001","article-title":"Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: a systematic review and meta-analysis","volume":"15","author":"Moulis","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2023.101141_bb0805","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejim.2020.10.011","article-title":"Risk of thrombosis, pregnancy morbidity or death in antiphospholipid antibodies positive patients with or without thrombocytopenia","volume":"84","author":"Moulinet","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.blre.2023.101141_bb0810","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejim.2020.01.017","article-title":"Thrombocytopenia in primary antiphospholipid syndrome, a marker of high-risk patients?","volume":"74","author":"Yelnik","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.blre.2023.101141_bb0815","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2023.101141_bb0820","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11912-019-0838-7","article-title":"Immune-mediated cytopenias after hematopoietic cell transplantation: pathophysiology, clinical manifestations, diagnosis, and treatment strategies","volume":"21","author":"Michniacki","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.blre.2023.101141_bb0825","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.bbmt.2018.12.842","article-title":"Immune cytopenias after ex vivo CD34+-selected allogeneic hematopoietic cell transplantation","volume":"25","author":"Scordo","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101141_bb0830","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fped.2019.00171","article-title":"Autoimmune cytopenias in pediatric hematopoietic cell transplant patients","volume":"7","author":"Neely","year":"2019","journal-title":"Front Pediatr"},{"key":"10.1016\/j.blre.2023.101141_bb0835","doi-asserted-by":"crossref","first-page":"316.e1","DOI":"10.1016\/j.jtct.2021.01.015","article-title":"Characterizing immune-mediated cytopenias after allogeneic hematopoietic cell transplantation for pediatric nonmalignant disorders","volume":"27","author":"Galvin","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.blre.2023.101141_bb0840","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3390\/cells10082051","article-title":"Hematopoietic dysfunction during graft-versus-host disease: a self-destructive process?","volume":"10","author":"M\u00fcskens","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.blre.2023.101141_bb0845","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbmt.2019.07.022","article-title":"Predictors for autoimmune cytopenias after allogeneic hematopoietic cell transplantation in children","volume":"26","author":"Szanto","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101141_bb0850","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5045\/br.2017.52.2.119","article-title":"Treatment and response of autoimmune cytopenia occurring after allogeneic hematopoietic cell transplantation in children","volume":"52","author":"Hwang-Bo","year":"2017","journal-title":"Blood Res"},{"key":"10.1016\/j.blre.2023.101141_bb0855","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2023.101141_bb0860","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0865","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101141_bb0870","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood.2022017015","article-title":"Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL","volume":"140","author":"Rejeski","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0875","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0880","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41375-022-01723-w","article-title":"Molecular landscape of immune pressure and escape in aplastic anemia","volume":"37","author":"Pagliuca","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2023.101141_bb0885","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.22.00710","article-title":"Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria","volume":"41","author":"Gurnari","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101141_bb0890","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021012900","article-title":"The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders","author":"Pagliuca","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0895","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/bloodadvances.2018027862","article-title":"Subclonal STAT3 mutations solidify clonal dominance","volume":"3","author":"Kerr","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101141_bb0900","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.seminhematol.2021.12.002","article-title":"Aplastic anemia: pathophysiology","volume":"59","author":"Giudice","year":"2022","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb0905","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3324\/haematol.2017.176701","article-title":"Deep sequencing and flow cytometric characterization of expanded effector memory CD8+CD57+ T cells frequently reveals T-cell receptor V\u03b2 oligoclonality and CDR3 homology in acquired aplastic anemia","volume":"103","author":"Giudice","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101141_bb0910","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.149080","article-title":"Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation","volume":"6","author":"Pagliuca","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.blre.2023.101141_bb0915","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/bjh.16336","article-title":"Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation","volume":"189","author":"Awada","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb0920","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/bmt.2013.5","article-title":"Large granular lymphocytosis and its impact on long-term clinical outcomes following Allo-SCT","volume":"48","author":"Kim","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101141_bb0925","doi-asserted-by":"crossref","first-page":"260.e1","DOI":"10.1016\/j.jtct.2020.12.008","article-title":"Large granular lymphocytosis with cytopenias after allogeneic blood or marrow transplantation: clinical characteristics and response to immunosuppressive therapy","volume":"27","author":"Messmer","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.blre.2023.101141_bb0930","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022017015","article-title":"Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T for Richter transformed DLBCL","author":"Rejeski","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0935","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3389\/fimmu.2020.02017","article-title":"Autoimmunity following allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Buxbaum","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0940","doi-asserted-by":"crossref","first-page":"1199422","DOI":"10.3389\/fimmu.2023.1199422","article-title":"Complex interactions of cellular players in chronic graft-versus-host disease","volume":"14","author":"Gail","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2023.101141_bb0945","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.169732","article-title":"Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD","volume":"8","author":"Poe","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.blre.2023.101141_bb0950","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101141_bb0955","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5045\/br.2022.2022043","article-title":"Management of immune thrombocytopenia: 2022 update of Korean experts recommendations","volume":"57","author":"Park","year":"2022","journal-title":"Blood Res"},{"key":"10.1016\/j.blre.2023.101141_bb0960","author":"Protocole National de Diagnostic et de Soins (PNDS)"},{"key":"10.1016\/j.blre.2023.101141_bb0965","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/jth.14227","article-title":"Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults","volume":"16","author":"Piel-Julian","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2023.101141_bb0970","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(01)07219-1","article-title":"Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study","volume":"358","author":"K\u00fchne","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2023.101141_bb0975","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9343(99)80342-8","article-title":"Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2023.101141_bb0980","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood-2012-12-466375","article-title":"Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the intercontinental cooperative ITP study group (ICIS)","volume":"121","author":"Neunert","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0985","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial","volume":"127","author":"Wei","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb0990","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate Mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101141_bb0995","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3026(21)00240-4","article-title":"All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"8","author":"Huang","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb1000","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/ajh.25989","article-title":"High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: a prospective, multicenter, randomized trial","volume":"95","author":"Yu","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb1005","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2012-09-455691","article-title":"Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia","volume":"121","author":"Gudbrandsdottir","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1010","author":"Assistance Publique - H\u00f4pitaux de Paris"},{"key":"10.1016\/j.blre.2023.101141_bb1015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajh.26378","article-title":"Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: new insights for an old treatment","volume":"97","author":"Mageau","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb1020","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00277-007-0317-3","article-title":"Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis","volume":"86","author":"Garcia-Chavez","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb1025","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2008-01-131029","article-title":"Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study","volume":"112","author":"Godeau","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1030","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/blood-2011-08-374777","article-title":"A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia","volume":"119","author":"Arnold","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1035","first-page":"99","article-title":"A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia","volume":"27","author":"Saleh","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2023.101141_bb1040","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1034\/j.1600-0609.2002.02686.x","article-title":"Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study","volume":"69","author":"Giagounidis","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb1050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20276","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura","volume":"78","author":"Braendstrup","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb1055","first-page":"538","article-title":"B-cell compartment as the selective target for the treatment of immune thrombocytopenias","volume":"88","author":"Zaja","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101141_bb1060","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","article-title":"The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura","volume":"125","author":"Cooper","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb1065","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.exphem.2006.02.009","article-title":"Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia","volume":"34","author":"Zaja","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb1070","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/pbc.21757","article-title":"One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab","volume":"52","author":"Mueller","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2023.101141_bb1075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2023.101141_bb1080","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1085","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","article-title":"Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2023.101141_bb1090","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","article-title":"A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia","volume":"123","author":"Bussel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1095","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb1100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-021-01047-9","article-title":"A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101141_bb1105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2023.101141_bb1110","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101141_bb1115","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/09537104.2019.1624709","article-title":"Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP)","volume":"31","author":"Kapur","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2023.101141_bb1120","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjh.18309","article-title":"Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia","volume":"198","author":"Pizzi","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb1125","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/09537104.2016.1235691","article-title":"Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP)","volume":"28","author":"Gudbrandsdottir","year":"2017","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2023.101141_bb1130","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149856","article-title":"Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia","volume":"132","author":"Guan","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2023.101141_bb1135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2109965","article-title":"Eltrombopag added to immunosuppression in severe aplastic Anemia","volume":"386","author":"Peffault de Latour","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101141_bb1140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.seminhematol.2020.12.002","article-title":"TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics","volume":"58","author":"Guan","year":"2021","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb1145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2020.11.009","article-title":"Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells","volume":"58","author":"Jha","year":"2021","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb1150","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022018665","article-title":"Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study","author":"Guillet","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1155","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s40264-015-0337-1","article-title":"Signal for thrombosis with Eltrombopag and Romiplostim: a disproportionality analysis of spontaneous reports within VigiBase\u00ae","volume":"38","author":"Nguyen","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.blre.2023.101141_bb1160","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103581","article-title":"Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: a systematic review and meta-analysis","volume":"171","author":"Tjepkema","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb1165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.autrev.2015.11.001","article-title":"Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: a systematic review and meta-analysis","volume":"15","author":"Moulis","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2023.101141_bb1170","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/key119","article-title":"Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists","volume":"57","author":"Guitton","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.blre.2023.101141_bb1175","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032949","article-title":"Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag a case series and literature review","volume":"102","author":"Garra","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.blre.2023.101141_bb1180","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood.V98.6.1760","article-title":"Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study","volume":"98","author":"Diz-K\u00fc\u00e7\u00fckkaya","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1185","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb1190","series-title":"Real-world use of fostamatinib in France. Interim results of a National Registry","first-page":"1613","author":"Moulis","year":"2023"},{"key":"10.1016\/j.blre.2023.101141_bb1195","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1182\/blood-2016-03-704734","article-title":"Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia","volume":"128","author":"Mah\u00e9vas","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1200","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/09537104.2018.1513476","article-title":"Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content","volume":"30","author":"Revilla","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2023.101141_bb1205","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood.2019003599","article-title":"Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment","volume":"135","author":"Miltiadous","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1210","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb1215","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101141_bb1220","author":"UCB Biopharma SRL"},{"key":"10.1016\/j.blre.2023.101141_bb1225","author":"argenx"},{"key":"10.1016\/j.blre.2023.101141_bb1230","author":"Harbour BioMed (Guangzhou) Co. Ltd"},{"key":"10.1016\/j.blre.2023.101141_bb1235","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2023.101141_bb1240","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2017-06-789578","article-title":"BAFF and CD4+ T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context","volume":"131","author":"Thai","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1245","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3324\/haematol.2020.259481","article-title":"Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial","volume":"106","author":"Mah\u00e9vas","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101141_bb1250","author":"Assistance Publique - H\u00f4pitaux de Paris"},{"key":"10.1016\/j.blre.2023.101141_bb1255","author":"Novartis Pharmaceuticals"},{"key":"10.1016\/j.blre.2023.101141_bb1260","author":"Novartis Pharmaceuticals"},{"key":"10.1016\/j.blre.2023.101141_bb1265","doi-asserted-by":"crossref","DOI":"10.1002\/art.42462","article-title":"Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell\u2013related autoimmune diseases","author":"Evans","year":"2023","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2023.101141_bb1270","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1182\/blood-2014-03-563445","article-title":"Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia","volume":"124","author":"Audia","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1275","author":"Pfizer"},{"key":"10.1016\/j.blre.2023.101141_bb1280","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1097\/MJT.0000000000000517","article-title":"Bortezomib for refractory immune-mediated thrombocytopenia Purpura","volume":"25","author":"Beckman","year":"2018","journal-title":"Am J Ther"},{"key":"10.1016\/j.blre.2023.101141_bb1285","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00277-022-05035-y","article-title":"Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab","volume":"102","author":"Str\u00fc\u00dfmann","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb1290","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3324\/haematol.2021.279232","article-title":"Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia","volume":"106","author":"Crickx","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101141_bb1295","author":"Ostfold Hospital Trust"},{"key":"10.1016\/j.blre.2023.101141_bb1300","author":"Takeda"},{"key":"10.1016\/j.blre.2023.101141_bb1305","author":"Hutchison Medipharma Limited"},{"key":"10.1016\/j.blre.2023.101141_bb1310","author":"Oscotec Inc"},{"key":"10.1016\/j.blre.2023.101141_bb1315","author":"Beijing InnoCare Pharma Tech Co., Ltd"},{"key":"10.1016\/j.blre.2023.101141_bb1320","author":"Hou"},{"key":"10.1016\/j.blre.2023.101141_bb1325","author":"Principia Biopharma, a Sanofi Company"},{"key":"10.1016\/j.blre.2023.101141_bb1330","author":"Bioverativ, a Sanofi company"},{"key":"10.1016\/j.blre.2023.101141_bb1335","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1340","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/17843286.2021.1876310","article-title":"Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian hematology society","volume":"77","author":"Janssens","year":"2022","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.blre.2023.101141_bb1345","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/pbc.21013","article-title":"Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia","volume":"47","author":"Wr\u00f3bel","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2023.101141_bb1350","article-title":"Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts","volume":"160","author":"Oh","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb1355","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/jth.14809","article-title":"Management of major bleeds in patients with immune thrombocytopenia","volume":"18","author":"Mithoowani","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2023.101141_bb1360","article-title":"Immune thrombocytopenia and pregnancy: an exposed\/non-exposed cohort study","author":"Guillet","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1365","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/rheumatology\/kev405","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part II: analgesics and other drugs used in rheumatology practice","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.blre.2023.101141_bb1370","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.blre.2023.101141_bb1375","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2023.101141_bb1380","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1182\/blood.2020007594","article-title":"Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study","volume":"136","author":"Michel","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1385","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1080\/14767058.2016.1222365","article-title":"Safety of splenectomy during pregnancy","volume":"30","author":"Bleau","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.blre.2023.101141_bb1390","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-201778","article-title":"Splenectomy during pregnancy: treatment of refractory immune thrombocytopenic purpura","volume":"2013","author":"Mahey","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.blre.2023.101141_bb1395","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/1753495X18778489","article-title":"Rituximab - a novel therapy for severe ITP in pregnancy: a case report","volume":"12","author":"Donohoe","year":"2019","journal-title":"Obstet Med"},{"key":"10.1016\/j.blre.2023.101141_bb1400","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1701-2163(16)34741-7","article-title":"Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura","volume":"32","author":"Gall","year":"2010","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.blre.2023.101141_bb1405","author":"Gaffet","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101141_bb1410","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/17474086.2021.2009337","article-title":"Efficacy and safety of thrombopoietin receptor agonists in the treatment of thrombocytopenia after hematopoietic stem cell transplantation: a meta-analysis and systematic review","volume":"14","author":"Yao","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb1415","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.bbmt.2019.12.003","article-title":"Use of Thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation","volume":"26","author":"Mahat","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101141_bb1420","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.bbmt.2019.05.023","article-title":"Thrombopoietin receptor agonists for severe thrombocytopenia after allogeneic stem cell transplantation: experience of the Spanish group of hematopoietic stem cell transplant","volume":"25","author":"Bento","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101141_bb1425","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/MPH.0000000000001263","article-title":"Eltrombopag for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation in children","volume":"41","author":"Li","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101141_bb1430","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12185-015-1821-1","article-title":"Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children","volume":"102","author":"Maximova","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2023.101141_bb1435","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.2019000358","article-title":"Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1\/2 multicenter trial","volume":"135","author":"Peffault de Latour","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1440","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101141_bb1445","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2018-11-884486","article-title":"Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-\u03b3","volume":"133","author":"Alvarado","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1450","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101141_bb1455","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic Anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:30:20Z","timestamp":1759437020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23001029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":291,"alternative-id":["S0268960X23001029"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101141","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The many facets of immune-mediated thrombocytopenia: Principles of immunobiology and immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101141"}}